Affymetrix Microarrays Used to Detect Thousands of Pathogens, Including Anthrax and Plague; AMB Features Two Interviews with Res
January 18 2006 - 8:00AM
Business Wire
The Affymetrix Microarray Bulletin (AMB) today published interviews
with researchers from Lawrence Berkeley National Laboratory and The
Naval Medical Research Center, who are using Affymetrix
(Nasdaq:AFFX) microarrays to detect thousands of different
pathogens, including anthrax and plague. Researchers Find Pathogens
in Unlikely Places Using High-density Microarrays LBNL's Gary
Andersen discusses the surprising organisms they are finding in
normal environmental samples Anthrax Genetic Discovery Provides
Basis for New Biodefense Test NMRC's Michael Zwick and Timothy Read
discuss how microarrays that resequence the entire anthrax genome
may help the military detect novel anthrax strains To view the
complete stories, please visit:
http://microarraybulletin.com/community. Affymetrix Microarray
Bulletin (AMB) is a magazine published by Affymetrix, Inc.
(Nasdaq:AFFX) that highlights leading microarray research and
diagnostic developments around the world. AMB features interviews
by and for scientists, statisticians and software engineers -- one
expert interviewing another. Our goal is to create a forum where
this community can discuss research and share new resources and
information. For more information about AMB, please visit the
publication's website at www.microarraybulletin.com. About
Affymetrix: Affymetrix scientists invented the world's first
high-density microarray in 1989 and began selling the first
commercial microarray in 1994. Since then, Affymetrix GeneChip(R)
technology has become the industry standard in molecular biology
research. Affymetrix technology is used by the world's top
pharmaceutical, diagnostic and biotechnology companies as well as
leading academic, government and not-for-profit research
institutes. More than 1,300 systems have been installed around the
world and nearly 4,000 peer-reviewed papers have been published
using the technology. Affymetrix' patented photolithographic
manufacturing process provides the most information capacity
available today on an array, enabling researchers to use a
whole-genome approach to analyzing the relationship between
genetics and health. Affymetrix is headquartered in Santa Clara,
Calif. with subsidiaries in Europe and Asia, as well as
manufacturing facilities in Sacramento, Calif. and Bedford, Mass.
The company has about 1,000 employees worldwide. For more
information about Affymetrix, please visit the company's website at
www.Affymetrix.com. NOTE: Affymetrix, the Affymetrix logo, and
GeneChip are registered trademarks owned or used by Affymetrix Inc.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024